4D Molecular TherapeuticsFDMT
Recorded

4D Molecular Therapeutics Guggenheim 3rd Annual Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Eddie HickmanBiotech Analyst

All right. Welcome back to the Guggenheim Healthcare Innovation Conference. My name is Eddie Hickman, one of the biotech analysts here. I am welcomed now by two members of the 4D Molecular Therapeutics team, CFO Kristian Humer and Chief Commercial and Business Officer Chris Simms. Gentlemen, thank you so much for joining us. Chris, I know you have a presentation prepared, so maybe for those who aren't familiar with the story, maybe give a brief overview, and then we'll get into Q&A.

Chris SimmsCCBO

Yeah, happy to. So hi, everyone, and Eddie, thanks for the opportunity to be here. As Eddie mentioned, Chris Simms, Chief Commercial and Business Officer. I'll take you through a little bit of a presentation that gives you a bit of an overview of our company, what we see as the opportunity, and more detail on our lead asset. But before I do that, Eddie, to your question, a little bit on 4DMT. 4DMT is a genetic medicines company founded about 13 years ago, headquartered in the Bay Area. What's unique about us is that we take a very different approach, and we'll talk a little bit more about this, to how we actually develop key vectors to deliver our genetic medicines.

Chris SimmsCCBO

We leverage technology that's Nobel Prize-winning out of Berkeley that basically uses directed evolution to select vectors that are super targeted to the tissues that they need to transduce and deliver the medicine, and by implication of that, don't transduce cells that they shouldn't connect with. Company, as I mentioned, been around for about 13 years. We're super excited. Our lead program that I'll go through in a few moments is in phase III. We expect top-line data on that program in the second quarter of next year, in the second half. It's for wet AMD, and again, I'll go through that in more detail in the slides here. Maybe I'll just take the next 10 minutes or so and go through the slides.

Chris SimmsCCBO

Please do, yeah. if that helps.

Chris SimmsCCBO

Thank you. So as a reminder, I may be making some forward-looking statements.

Chris SimmsCCBO

There's more information, of course, about our SEC filings that can be found on our website. A couple of key takeaways from my short presentation today. First and foremost, our lead asset, again, is called 4D-150, we believe has the potential to establish a new treatment paradigm for wet AMD. For your audience, if they're not familiar with the size of the wet AMD category, or broadly the anti-VEGF category that's used to treat retinal disease, the category globally is worth about $16 billion and has been growing steadily. And despite that size of that category, there's still significant unmet need that, again, I'll go through in a few moments, that we believe we are uniquely positioned to address. A bit of a shameless plug.

Chris SimmsCCBO

I don't have a lot of time to go through all of the commercial opportunity here today, but if you reference our website, we recently had an R&D Investor Day focused largely actually on the commercial opportunity, wherein we go through a lot more of the detail as to why we think the commercial opportunity is quite significant for 4D-150. Some of the other key takeaways that we think are important. First of all, we believe 4D-150 as a backbone therapy has the potential for lifelong continuous disease control from a single dose. The target product profile of 4D-150 is that we believe it can meet needs of both patients by preserving their vision while significantly reducing the treatment burden, and with the opportunity for injection freedom. A little bit more on that. The current standard of care is frequent bolus injections into your eye of anti-VEGF.

Chris SimmsCCBO

Those therapies are highly efficacious. We know they work well. However, as I'm sure you can appreciate, a patient needs to go to a doctor's office on some frequency. For some patients, that's monthly. For others, it's every two months or three months, depends upon your treatment need. But over time, that creates significant treatment burden, both for the patient, their caregivers, and so on. What happens in the real world is that patients ultimately are not treated as frequently as they need to be, and therefore they lose vision that otherwise they should be gaining. Our profile, we believe, has the potential with a single injection which delivers the medicine they need continuously. We can help a patient preserve that vision for the rest of their lives, we think, with the potential for significant treatment burden reduction.

Chris SimmsCCBO

The other key takeaway is that our phase III program and our phase III design, we think, is set up to position us for success, and I'll go through a little bit more as to what that design looks like. I think very importantly from a commercial perspective, patients, physicians, and payers together, we think, are expected to be excited, and evidence so far in the work we've done would suggest that we meet the needs of all those stakeholders. We think by doing so, we can drive significant commercial adoption. A little bit on the science, why we think we're uniquely positioned to achieve what I just described. 4D-150 is designed for targeted delivery of aflibercept, producing transgenes to the retina with a single intravitreal injection.

Chris SimmsCCBO

Core to the product design, and it's unique to us, and it comes out of this science that I referenced earlier, is the R100 capsid that was developed internally. It's proprietary to us. What that R100 capsid allows us to do is three things that are really important. First, it allows us to take a low-dose approach and deliver the medicine through an intravitreal injection. An IVT injection is a procedure that physicians know well. They do it hundreds of times today with existing therapies. The reason that's important, that other therapies, gene therapies in development take a subretinal or surgical approach. Being able to deliver intravitreally is a huge advantage when it comes to adoption. Our capsid also allows us to target the retinal cells specifically and not transduce cells that we shouldn't be transducing.

Chris SimmsCCBO

Therefore, I think, and the third thing is that then has an implication for the dose, but also then has an implication for what we believe is a very favorable toxicity and safety profile, which is critical for gene therapies. Of course, we provide or we combine our R100 capsid with a therapeutic payload that includes aflibercept. When you put those two things together and you deliver it to the retinal cells where it's needed the most, you get long-term expression and we believe long-term disease control. A little bit on what's different about us and what the unmet need is. Very simply, what this slide tells us is that wet AMD is a chronic disease.

Chris SimmsCCBO

It's always there, and today it's treated episodically, right, through bolus injections at some level of frequency. We think the ideal match or the ideal therapy, rather, is a therapy that treats the disease with a chronic therapy, and that's where we get excited about a backbone therapy of 4D-150, where it's always on, it's always treating the disease, as opposed to the episodic nature of treatment today. We believe if you match the therapy with the biology of the disease, you get much better outcomes. That's in essence what we show here with our positioning around being a continuous backbone therapy, where in essence, we know the disease is always present, and a therapy like 4D-150 that is continuously producing the drug that treats the disease, we think is the ideal match.

Chris SimmsCCBO

What that translates to is that today in the real world, what happens is that patients actually come in, they're diagnosed, and quite often they get a couple of early bolus shots of anti-VEGF and they gain vision, which is great, right? Vision, they gain five to 10 letters in vision upon initiation of therapy. However, because of the treatment burden that I described earlier, it's quite common that over time, a lot of patients fall off therapy or they become undertreated. That results in that vision that they initially gained, they lose it, and therefore, we think that creates a continuous control gap. Therefore, the opportunity with a backbone therapy is to preserve that initial gain of vision and allow a patient to do that while also significantly reducing the treatment that goes along with that over the life of the patient.

Chris SimmsCCBO

This slide just highlights some high-level results that we've generated through our program development so far. What we show here is the two-year results of the recently diagnosed patient population. Our phase I/II PRISM study looked at wet AMD patients across a broad range. We showed data on patients that had a high burden, and then we saw data on patients that had more moderate burden, as well as patients that were more recently diagnosed. We show the recently diagnosed patient population on this slide because it most resembles the patients that we're studying in our phase III program, and the results that we saw through our phase II with this patient population were quite astounding. We're out to two years.

Chris SimmsCCBO

You see in the top left, you see that central subfield thickness, or CST, a marker of anatomy, was very controlled, and as well on the bottom, you see that best corrected visual acuity. Remember in the previous slide, I showed that most patients, that vision falls off. We actually showed that maintenance of vision, again, out to two years. Importantly, we did that with an average of 1.66 supplemental injections over that two-year period. When you compared that to what a patient would have had to receive if they were treated on label with the standard of care, which is EYLEA, if they were getting treated Q8 with EYLEA over that two-year period, they would have been on pace to get 12 injections. Think about the impact of that to a patient.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day